Mechanism of action

The mechanism of action of KPV is only partially understood. Review literature on α-MSH describes KPV as its C-terminal tripeptide, in which the anti-inflammatory effect is preserved while the pigmentary action is absent (Brzoska et al., 2008). The best-documented mechanistic observation comes from Dalmasso et al. (2008): in intestinal epithelial and immune cells, the tripeptide is taken up into the cell via the oligopeptide transporter PepT1, where at nanomolar concentrations it inhibited the pro-inflammatory NF-κB and MAPK signalling pathways, with reduced cytokine production as a consequence. In mouse models of colitis (DSS- and TNBS-induced), KPV given orally in the drinking water reduced inflammatory activity in that study. Whether melanocortin receptors are additionally involved is unresolved: according to Brzoska et al. (2010), KPV lacks the entire sequence motif that would be required for binding to any of the known melanocortin receptors, and the exact signalling mechanism of KPV is unknown. Experimentally, KPV also acted in mice with a non-functional melanocortin-1 receptor (MC1Re/e); the authors read these effects as at least partially independent of MC1R signalling (Kannengiesser et al., 2008). No published human pharmacokinetic data exist, including any systemic half-life. On stability, only analytical literature is available: under acid, alkali and peroxide stress in aqueous solution, a lys-pro-diketopiperazine formed as the major degradation product (Pawar et al., 2015); evidence of enzymatic lability is only indirect, in that glycoalkylated KPV analogs showed stability toward proteolytic enzymes (Songok et al., 2018). More recent work has investigated carrier systems such as hyaluronic acid-functionalized nanoparticles for oral, colon-targeted delivery in a mouse model of ulcerative colitis (Xiao et al., 2017).

State of evidence

The evidence on KPV is exclusively preclinical: in vitro data and mouse models exist, but the cited sources provide no completed randomized controlled human trial and do not establish authorization of a particular KPV product. Core findings are PepT1-mediated uptake with NF-κB and MAPK inhibition and the attenuation of DSS- and TNBS-induced colitis in mice (Dalmasso et al., 2008). An independent group reported anti-inflammatory effects in further murine IBD models, DSS colitis and CD45RBhi transfer colitis (Kannengiesser et al., 2008), but did not test the PepT1 mechanism. One study in a mouse model of colitis-associated carcinogenesis described therapeutic effects of KPV alongside a disease-promoting role of the transporter PepT1 (Viennois et al., 2016); the nanoparticle work on oral delivery has likewise been limited to mice (Xiao et al., 2017). The source base is narrower than the number of studies suggests: the PepT1 mechanism and the nanoparticle work all come from the same laboratory (Merlin and colleagues); the only finding independently replicated so far is the anti-inflammatory effect in murine colitis models (Kannengiesser et al., 2008). The specifically cited intestinal studies include oral or luminal exposure: Dalmasso studied KPV in drinking water, Xiao investigated a colon-targeted carrier, and Viennois et al. (2016) reported absence of the examined KPV effect in PepT1-deficient mice. These conditions support interpretation of those particular intestinal models, not a claim that every in-vivo KPV effect requires luminal exposure or PepT1. They do not establish systemic effects in humans. Alongside this, a smaller dermatological line exists: in human HaCaT keratinocytes and in a three-dimensional skin model, KPV attenuated inflammation and apoptosis induced by fine particulate matter (PM10) (Sung et al., 2025); permeation experiments on dermatomed human skin found that KPV does not penetrate detectably by passive diffusion and crosses the skin only under iontophoresis or with microneedles (Pawar et al., 2017). Whether these model findings translate to humans is unknown: effect sizes, safety and long-term behaviour in humans are uncharacterized. No conclusions on efficacy or safety can be drawn from the available data.

Storage and handling

Pawar et al. (2015) examined KPV in aqueous solution under forced acid, alkaline and peroxide stress and identified lys-pro-diketopiperazine as a major degradation product. These accelerated analytical conditions do not establish storage duration, shelf life or handling requirements for a particular formulation.

Questions about the research

What is KPV studied for in research?

KPV is studied primarily as an anti-inflammatory fragment of α-MSH, with a focus on models of chronic inflammatory bowel disease: cell culture studies on PepT1-mediated uptake and NF-κB/MAPK inhibition, and mouse models of colitis and colitis-associated carcinogenesis. It also serves as a tool in melanocortin research to investigate which partial sequences of α-MSH carry its anti-inflammatory activity. A smaller line of work addresses skin cells and permeation across human skin, and more recent work additionally addresses carrier systems for targeted oral delivery to the gut.

What is the state of the evidence on KPV?

The evidence base consists exclusively of in vitro studies and animal models, predominantly in mice, and a large share of it comes from a single laboratory. The cited sources provide no completed randomized controlled human trial and do not establish authorization of a particular KPV product. Reliable published human pharmacokinetic data, such as a half-life, are also lacking. No conclusions on efficacy or safety in humans can be drawn from this evidence.

Sources

1. Dalmasso et al., Gastroenterology 2008DOI: 10.1053/j.gastro.2007.10.026PMID: 18061177
2. Kannengiesser et al., Inflammatory Bowel Diseases 2008DOI: 10.1002/ibd.20334PMID: 18092346
3. Brzoska et al., Endocrine Reviews 2008, review of alpha-MSH and related anti-inflammatory peptidesDOI: 10.1210/er.2007-0027PMID: 18612139
4. Brzoska et al., Adv Exp Med Biol 2010, review chapter on alpha-MSH-derived anti-inflammatory peptidesDOI: 10.1007/978-1-4419-6354-3_8PMID: 21222263
5. Pawar et al., Biomedical Chromatography 2015 (solution stability)DOI: 10.1002/bmc.3347PMID: 25298219
6. Viennois et al., Cellular and Molecular Gastroenterology and Hepatology 2016DOI: 10.1016/j.jcmgh.2016.01.006PMID: 27458604
7. Xiao et al., Molecular Therapy 2017DOI: 10.1016/j.ymthe.2016.11.020PMID: 28143741
8. Pawar et al., Journal of Pharmaceutical Sciences 2017 (skin permeation)DOI: 10.1016/j.xphs.2017.03.017PMID: 28343991
9. Songok et al., PLoS One 2018DOI: 10.1371/journal.pone.0199686PMID: 29953505
10. Sung et al., Tissue and Cell 2025DOI: 10.1016/j.tice.2025.102837PMID: 40073467

Mechanism of action

The mechanism of action of KPV is only partially understood. Review literature on α-MSH describes KPV as its C-terminal tripeptide, in which the anti-inflammatory effect is preserved while the pigmentary action is absent (Brzoska et al., 2008). The best-documented mechanistic observation comes from Dalmasso et al. (2008): in intestinal epithelial and immune cells, the tripeptide is taken up into the cell via the oligopeptide transporter PepT1, where at nanomolar concentrations it inhibited the pro-inflammatory NF-κB and MAPK signalling pathways, with reduced cytokine production as a consequence. In mouse models of colitis (DSS- and TNBS-induced), KPV given orally in the drinking water reduced inflammatory activity in that study. Whether melanocortin receptors are additionally involved is unresolved: according to Brzoska et al. (2010), KPV lacks the entire sequence motif that would be required for binding to any of the known melanocortin receptors, and the exact signalling mechanism of KPV is unknown. Experimentally, KPV also acted in mice with a non-functional melanocortin-1 receptor (MC1Re/e); the authors read these effects as at least partially independent of MC1R signalling (Kannengiesser et al., 2008). No published human pharmacokinetic data exist, including any systemic half-life. On stability, only analytical literature is available: under acid, alkali and peroxide stress in aqueous solution, a lys-pro-diketopiperazine formed as the major degradation product (Pawar et al., 2015); evidence of enzymatic lability is only indirect, in that glycoalkylated KPV analogs showed stability toward proteolytic enzymes (Songok et al., 2018). More recent work has investigated carrier systems such as hyaluronic acid-functionalized nanoparticles for oral, colon-targeted delivery in a mouse model of ulcerative colitis (Xiao et al., 2017).

State of evidence

The evidence on KPV is exclusively preclinical: in vitro data and mouse models exist, but the cited sources provide no completed randomized controlled human trial and do not establish authorization of a particular KPV product. Core findings are PepT1-mediated uptake with NF-κB and MAPK inhibition and the attenuation of DSS- and TNBS-induced colitis in mice (Dalmasso et al., 2008). An independent group reported anti-inflammatory effects in further murine IBD models, DSS colitis and CD45RBhi transfer colitis (Kannengiesser et al., 2008), but did not test the PepT1 mechanism. One study in a mouse model of colitis-associated carcinogenesis described therapeutic effects of KPV alongside a disease-promoting role of the transporter PepT1 (Viennois et al., 2016); the nanoparticle work on oral delivery has likewise been limited to mice (Xiao et al., 2017). The source base is narrower than the number of studies suggests: the PepT1 mechanism and the nanoparticle work all come from the same laboratory (Merlin and colleagues); the only finding independently replicated so far is the anti-inflammatory effect in murine colitis models (Kannengiesser et al., 2008). The specifically cited intestinal studies include oral or luminal exposure: Dalmasso studied KPV in drinking water, Xiao investigated a colon-targeted carrier, and Viennois et al. (2016) reported absence of the examined KPV effect in PepT1-deficient mice. These conditions support interpretation of those particular intestinal models, not a claim that every in-vivo KPV effect requires luminal exposure or PepT1. They do not establish systemic effects in humans. Alongside this, a smaller dermatological line exists: in human HaCaT keratinocytes and in a three-dimensional skin model, KPV attenuated inflammation and apoptosis induced by fine particulate matter (PM10) (Sung et al., 2025); permeation experiments on dermatomed human skin found that KPV does not penetrate detectably by passive diffusion and crosses the skin only under iontophoresis or with microneedles (Pawar et al., 2017). Whether these model findings translate to humans is unknown: effect sizes, safety and long-term behaviour in humans are uncharacterized. No conclusions on efficacy or safety can be drawn from the available data.

Storage and handling

Pawar et al. (2015) examined KPV in aqueous solution under forced acid, alkaline and peroxide stress and identified lys-pro-diketopiperazine as a major degradation product. These accelerated analytical conditions do not establish storage duration, shelf life or handling requirements for a particular formulation.

Questions about the research

What is KPV studied for in research?

KPV is studied primarily as an anti-inflammatory fragment of α-MSH, with a focus on models of chronic inflammatory bowel disease: cell culture studies on PepT1-mediated uptake and NF-κB/MAPK inhibition, and mouse models of colitis and colitis-associated carcinogenesis. It also serves as a tool in melanocortin research to investigate which partial sequences of α-MSH carry its anti-inflammatory activity. A smaller line of work addresses skin cells and permeation across human skin, and more recent work additionally addresses carrier systems for targeted oral delivery to the gut.

What is the state of the evidence on KPV?

The evidence base consists exclusively of in vitro studies and animal models, predominantly in mice, and a large share of it comes from a single laboratory. The cited sources provide no completed randomized controlled human trial and do not establish authorization of a particular KPV product. Reliable published human pharmacokinetic data, such as a half-life, are also lacking. No conclusions on efficacy or safety in humans can be drawn from this evidence.

Sources

1. Dalmasso et al., Gastroenterology 2008DOI: 10.1053/j.gastro.2007.10.026PMID: 18061177
2. Kannengiesser et al., Inflammatory Bowel Diseases 2008DOI: 10.1002/ibd.20334PMID: 18092346
3. Brzoska et al., Endocrine Reviews 2008, review of alpha-MSH and related anti-inflammatory peptidesDOI: 10.1210/er.2007-0027PMID: 18612139
4. Brzoska et al., Adv Exp Med Biol 2010, review chapter on alpha-MSH-derived anti-inflammatory peptidesDOI: 10.1007/978-1-4419-6354-3_8PMID: 21222263
5. Pawar et al., Biomedical Chromatography 2015 (solution stability)DOI: 10.1002/bmc.3347PMID: 25298219
6. Viennois et al., Cellular and Molecular Gastroenterology and Hepatology 2016DOI: 10.1016/j.jcmgh.2016.01.006PMID: 27458604
7. Xiao et al., Molecular Therapy 2017DOI: 10.1016/j.ymthe.2016.11.020PMID: 28143741
8. Pawar et al., Journal of Pharmaceutical Sciences 2017 (skin permeation)DOI: 10.1016/j.xphs.2017.03.017PMID: 28343991
9. Songok et al., PLoS One 2018DOI: 10.1371/journal.pone.0199686PMID: 29953505
10. Sung et al., Tissue and Cell 2025DOI: 10.1016/j.tice.2025.102837PMID: 40073467